Comparison of SARS-CoV-2 Hyperimmune Immunoglobulins Following Infection Plus Vaccination vs Infection

Lorenza Bellusci; Hana Golding; Surender Khurana

doi:10.1001/jamanetworkopen.2023.27307

Comparison of SARS-CoV-2 Hyperimmune Immunoglobulins Following Infection Plus Vaccination vs Infection

JAMA Netw Open. 2023 Aug 1;6(8):e2327307. doi: 10.1001/jamanetworkopen.2023.27307.

Authors

Lorenza Bellusci¹, Hana Golding¹, Surender Khurana¹

Affiliation

¹ Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.

No abstract available

Plain language summary

This cross-sectional study compares the neutralizing titers of convalescent plasma and hyperimmune anti–SARS-CoV-2 intravenous immunoglobulins against circulating Omicron subvariants.

Publication types

Research Support, U.S. Gov't, P.H.S.

MeSH terms

COVID-19*
Humans
Immunoglobulins / therapeutic use
SARS-CoV-2*

Substances

Immunoglobulins